Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxfordshire Local Enterprise Partnership (OxLEP) has secured funding to support the University of Oxford’s Clinical BioManufacturing Facility (CBF) – a UK leader in the production of vaccines for early phase clinical trials, including the Oxford-AstraZeneca vaccine.

Professor Catherine Green © John Cairns

The enabling works will see the refurbishment of the Clinical BioManufacturing Facility’s cleanroom and storage facilities, as well as enabling works in support of future expansion.

The further expansion will include the creation of additional clean rooms, providing space to deliver up to 10 clinical grade products (gene therapies, vaccines, biologics) to trial per year. This creates the potential to increase the UK's share of the global vaccine and biologics manufacturing market worth over £735 million.

The funding comes as part of the government’s Getting Building Fund, which aims to help kick-start the UK economy following the emergence of the COVID-19.

OxLEP – working with the University of Oxford – secured £200,000 of funding for CBF through the fund, with the total cost of the project being £250,000.

Read the full story on the University of Oxford website

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.